Determinants of the Effectiveness of Glucagon-Like Peptide-1 in Type 2 Diabetes
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
GLP-1 lowers blood glucose in fasting type 2 diabetic patients. To clarify the relation of the effect of GLP-1 to obesity, blood glucose, beta-cell function, and insulin sensitivity, GLP-1 (1.2 pmol/kg.min) was infused iv for 4-6 h into 50 fasting type 2 diabetic patients with a wide range of age, body mass index, HbA1c, and fasting plasma glucose. The effectiveness of GLP-1 was evaluated by calculation of a glucose disappearance constant for each individual (Kg, linear slope of log-transformed plasma glucose), and by the lowest stable glucose level (Nadir plasma glucose) obtained during the infusion. Grouped according to fasting plasma glucose (<10, 10-15, >15 mmol/liter), Kg values were 0.45 +/- 0.03, 0.38 +/- 0.04, and 0.28 +/- 0.04%/min (P = 0.005), and Nadir plasma glucose values were 4.7 +/- 0.1 (3.9-5.9), 5.8 +/- 0.4 (4.3-8.4), and 8.7 +/- 1.4 (6.2-18.7) mmol/liter (P = 0.0003). Nonresponders were not identified. Multiple regression analysis with Kg or Nadir plasma glucose as the dependent parameter and body mass index, age, gender, diabetes duration, and significantly correlated parameters (in multiple regression for Kg: fasting plasma glucose, fasting nonesterified fatty acid, dipeptidyl peptidase activity, peak insulin, and the logarithm of beta-cell function; and for Nadir plasma glucose: fasting plasma glucose, fasting nonesterified fatty acid, dipeptidyl peptidase activity, delta glucagon decrement, F-GLP-1 total, logarithm of beta-cell function, and Kg) as independent parameters resulted in fasting plasma glucose as the only significant predictor of Kg, and fasting plasma glucose and Kg as predictors of Nadir plasma glucose. Kg and Nadir plasma glucose were neither influenced by treatment nor by neuropathy per se. In conclusion, GLP-1 lowers plasma glucose in type 2 diabetes regardless of severity, but glucose elimination is faster and obtained glycemic level lower in patients with the lower fasting plasma glucose. Not all patients can be expected to reach normoglycemia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“GLP-1RAs represent a pharmacotherapeutic category of injectable hypoglycemic agents that are sanctioned as adjunctive therapies to diet and exercise for the management of type 2 diabetes mellitus (T2DM) in adult patients”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [7]
Citations
Cites
Correct Homeostasis Model Assessment (HOMA) Evaluation Uses the Computer Program
Levy, J. C., Matthews, D. R., & Hermans, M. P. (1998) · Diabetes Care · doi:10.2337/diacare.21.12.2191 · Cited by 2,013
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Self-citationXu, G., Stoffers, D. A., Habener, J. F., & Bonner-Weir, S. (1999) · Diabetes · doi:10.2337/diabetes.48.12.2270 · Cited by 1,209
Nauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092
Self-citationTissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans
Ørskov, C., Rabenhøj, L., Wettergren, A., Kofod, H., & Holst, J. J. (1994) · Diabetes · doi:10.2337/diab.43.4.535 · Cited by 919
Self-citationGutniak, M., Ørkov, C., Holst, J. J., Ahrén, B., & Efendić, S. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205143262003 · Cited by 868 · cited 1×
“HE INCRETIN HORMONE GLP-1 stimulates glucoseinduced insulin secretion and inhibits glucagon secretion (1, 2). As a result of these actions, hepatic glucose production and blood glucose concentrations decrease (3, 4). The ability of GLP-1 to modulate insulin and glucagon secretion is preserved in type 2 diabetic patien…”
BackgroundSelf-citationTruncated GLP-1 (proglucagon 78?107-amide) inhibits gastric and pancreatic functions in man
Wettergren, A., Schjoldager, B., Mortensen, P. E., Myhre, J., Christiansen, J., & Holst, J. J. (1993) · Digestive Diseases and Sciences · doi:10.1007/bf01316798 · Cited by 670
Self-citationTruncated glucagon‐like peptide I, an insulin‐releasing hormone from the distal gut
Holst, J. J., Ørskov, C., Vagn Nielsen, O., & Schwartz, T. W. (1987) · FEBS Letters · doi:10.1016/0014-5793(87)81430-8 · Cited by 615
Self-citationWillms, B., Werner, J., Holst, J. J., Orskov, C., Creutzfeldt, W., & Nauck, M. A. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.1.8550773 · Cited by 502 · cited 1×
“In nonfasting patients an inhibitory effect on gastric emptying rate adds to the glucose-lowering effect by delaying glucose entry and uptake from the intestine (10, 11 ).”
BackgroundSelf-citation
Cited by
Items 101–173 of 173
Individualised incretin-based treatment for type 2 diabetes
Nauck, M. A., & Meier, J. J. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60998-1 · Cited by 16
Redij, T., Ma, J., Li, Z., Hua, X., & Li, Z. (2019) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-019-00254-4 · Cited by 16
Kim, K., Yang, H. J., Choi, E., Shin, M. H., Kim, K., Um, J., Lee, B.-C., & Jang, H.-J. (2013) · Oriental Pharmacy and Experimental Medicine · doi:10.1007/s13596-013-0107-5 · Cited by 14
Unmet needs among patients with Type 2 diabetes and secondary failure to oral anti-diabetic agents
Pitocco, D., Valle, D. D. L. N. M., Rossi, A., & Gentilella, R. (2008) · Journal of Endocrinological Investigation · doi:10.1007/bf03346373 · Cited by 14
Incretin-Related Therapies in Type 2 Diabetes: A Practical Overview
Robertson, C. (2011) · Diabetes Spectrum · doi:10.2337/diaspect.24.1.26 · Cited by 14
Sennoside A Induces GLP-1 Secretion Through Activation of the ERK1/2 Pathway in L-Cells
Ma, L., Cao, X., Ye, X., Ye, J., & Sun, Y. (2020) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s247251 · Cited by 13
Lipid Effects of Endocrine Medications
Mihailescu, D. V., Vora, A., & Mazzone, T. (2010) · Current Atherosclerosis Reports · doi:10.1007/s11883-010-0146-z · Cited by 13
Nakamura, Y., Kanai∥, T., Saeki, K., Takabe, M., Irie, J., Miyoshi, J., Mikami, Y., Teratani, T., Suzuki, T., Miyata, N., et al. (2013) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00318.2012 · Cited by 13
The Gut: A Key to the Pathogenesis of Type 2 Diabetes?
Holst, J. J., Pedersen, J., Wewer Albrechtsen, N. J., & Knop, F. K. (2017) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2017.0015 · Cited by 11
Self-citationIncretin-based therapy: a new horizon in diabetes management
Zarei, M., Vaighan, N. S., Farjoo, M. H., Talebi, S., & Zarei, M. (2024) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-024-01479-3 · Cited by 13
Jiang, T., Zhou, Y., Zhu, J., Chen, Z., Sun, P. G., Zhang, Q., Wang, Z., Shao, Q., Jiang, X., Li, B., et al. (2015) · Archiv der Pharmazie · doi:10.1002/ardp.201500082 · Cited by 9
Onoja, S. O., Chimaobi, N. G., Maxwell, E., & Ndukaku, O. Y. (2017) · Journal of Complementary and Integrative Medicine · doi:10.1515/jcim-2015-0017 · Cited by 9
The Gut Microbiota and Effects on Metabolism
Hussey, S. E., & Bergman, M. A. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-386456-7.02009-8 · Cited by 9
Newmire, D. E., Rivas, E., Deemer, S. E., Willoughby, D. S., & Ben‐Ezra, V. (2019) · Nutrients · doi:10.3390/nu11112650 · Cited by 9
Balazki, P., Schaller, S., Eißing, T., & Lehr, T. (2020) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12520 · Cited by 9
Halmos, T., & Suba, I. (2011) · Orvosi Hetilap · doi:10.1556/oh.2011.28981 · Cited by 9
Dewi, N. P., Allia, R., & Sabang, S. M. (2016) · Proceeding of Mulawarman Pharmaceuticals Conferences · doi:10.25026/mpc.v3i2.88 · Cited by 8
Incretinas: Un nuevo paradigma en el tratamiento de la diabetes mellitus tipo 2
Blumenfeld, O. S. (2009) · Revista de Endocrinología y Nutrición · Cited by 8
Glucagon-like peptide 1 (GLP-1) and incretin mimetics for the treatment of diabetes
Nauck, M. A. (2005) · Practical Diabetes · doi:10.1002/pdi.801 · Cited by 8
Cho, B. (2018) · Materials Research Express · doi:10.1088/2053-1591/aafb3d · Cited by 6
Optimal diabetes management during medical weight loss for cardiovascular risk reduction
Janosz, K. E. N., Miller, W. M., Odom, J., Lillystone, M. A., Yanez, J., & McCullough, P. A. (2005) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.3.4.761 · Cited by 6
Pharmacological Risk Assessment for Dental Implants
Wu, X., & Tamimi, F. (2018) · Springer eBooks · doi:10.1007/978-3-319-71181-2_4 · Cited by 5
Nauck, M. A., Schmidt, W. E., & Meier, J. J. (2007) · Springer eBooks · doi:10.1007/978-0-387-69737-6_12 · Cited by 5
Torun, A. N., & Ertuğrul, D. T. (2015) · InTech eBooks · doi:10.5772/59241 · Cited by 4
Linking sequence to function in drug design with ancestral sequence reconstruction
Kodra, J. T., Skovgaard, M., Madsen, D., & Liberles, D. A. (2007) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780199299188.003.0003 · Cited by 4
Eriksen, R., White, M. C., Dawed, A. Y., García‐Pérez, I., Posma, J. M., Haid, M., Sharma, S., Prehn, C. P., Thomas, E. L., Koivula, R. W., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae119 · Cited by 3
Self-citationQuast, D. R., Lancaster, D., Xie, C., Bound, M. J., Grivell, J., Jones, K. L., Horowitz, M., Meier, J. J., Wu, T., Rayner, C. K., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15736 · Cited by 3
Predicting response to incretin-based therapy
Kalra, S., Kalra, B., Sahay, R. K., & Agrawal, N. K. (2011) · Research and Reports in Endocrine Disorders · doi:10.2147/rred.s16282 · Cited by 3
Wu, L., Gong, Q., Na, R., Mao, X., Zheng, X., Liu, Q., Ma, C., Ding, X., Sheng, H., & Liu, Z. (2015) · PubMed · Cited by 3
Haugaard, S. B., Andersen, O., Pedersen, S. B., Dela, F., Deacon, C. F., Holst, J. J., Iversen, J., & Madsbad, S. (2006) · HIV Medicine · doi:10.1111/j.1468-1293.2006.00364.x · Cited by 3
Self-citationGÓRSKA, A., & Arciszewski, M. B. (2020) · Medycyna Weterynaryjna · doi:10.21521/mw.6374 · Cited by 3
(2018) · Springer eBooks · doi:10.1007/978-3-319-71181-2 · Cited by 3
Chokrungvaranon, N., Chentanez, T., & Arakaki, R. F. (2007) · Endocrine · doi:10.1007/s12020-008-9042-5 · Cited by 3
Phenotypic and genomic frameworks for precision pharmacotherapy in obesity: a narrative review
López-Delgado, D. S., Reyes-Zermeño, M. G., Lemus, E. D. S., Acosta-Celis, C. G., Kantún-Marín, M. A., Gomez-Lujan, M., Fallaza-Moya, K., Muñoz-Chuquilín, O., Levano, S. E. T., Gutierrez-Chavez, G., et al. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1803474 · Cited by 2
Abdelhamid, A., Youssef, M., & Saber, S. (2022) · Delta University Scientific Journal · doi:10.21608/dusj.2022.275439 · Cited by 2
Behary, P., Godsland, I. F., & Baynes, K. (2014) · Practical Diabetes · doi:10.1002/pdi.1867 · Cited by 2
Achieving “PeaK-A” Insulin Secretion
Evans‐Molina, C., & Mirmira, R. G. (2013) · Diabetes · doi:10.2337/db13-0196 · Cited by 2
Ribeill, Y. (2013) · Wiley eBooks · doi:10.1002/9781118532331.ch1 · Cited by 2
Gilor, C. (2010) · Illinois Digital Environment for Access to Learning and Scholarship (University of Illinois at Urbana-Champaign) · Cited by 2
Effects of Different Immunosuppressive Drugs on Incretins in Renal Transplant Patients
Yılmaz, N., Sarı, R., Süleymanlar, G., & Özdem, S. (2020) · Journal of the National Medical Association · doi:10.1016/j.jnma.2020.03.012 · Cited by 2
Avogaro, A. (2008) · Giornale Ialiano di Cardiologia · doi:10.1714/630.7356 · Cited by 2
Dual GIP/GLP-1 Receptor Agonist Tirzepatide – a New Peak of Incretin-Based Therapy
Глинкина, И. В. (2026) · Effective Pharmacotherapy · doi:10.33978/2307-3586-2026-22-12-26-36 · Cited by 1
From Blood Sugar To Brain Health: Understanding Type 3 Diabetes and Alzheimer’s
Moitra, R., Nayak, S. S., Lokhandwala, Z., Desai, V., Patel, H. P., Patel, N., Sanjaykumar, D. V., & Patel, K. J. (2025) · Journal of Neonatal Surgery · Cited by 1
Gut as an Endocrine Organ: The Role of Nutrient Sensing in Energy Metabolism
Wang, M. (2011) · Wiley eBooks · doi:10.1002/9780470910016.ch1 · Cited by 1
Ostroukhova, E. N., Хмельницкий, О. К., Krasilnikova, E. I., & Давиденко, К. (2012) · Problems of Endocrinology · doi:10.14341/probl201258351-55 · Cited by 1
The Molecular Mechanisms Underlying Ligand Specificity of the Insulin and IGF-I Receptors
Tao, J.-L. (2010) · OhioLink ETD Center (Ohio Library and Information Network) · Cited by 1
Mipa, J., Bintari, S., & Artikel, S. (2012) · Cited by 1
Sharma, S. B. (2016) · Journal of Diabetes and Obesity · doi:10.15436/2376-0494.16.864 · Cited by 1
Muhammad, H. F. L., & Huriyati, E. (2018) · Paediatrica Indonesiana · doi:10.14238/pi57.5.2017.1516 · Cited by 1
The Effect of Alogliptin and Metformin Combination Therapy in Type 2 Diabetes: A Pilot Study
Kishimoto (2013) · Journal of Endocrinology and Metabolism · doi:10.4021/jem196e · Cited by 1
Song, Z. (2017) · TSpace (University of Toronto) · Cited by 1
Calleja, A. I. (2013) · UVaDOC UVaDOC University of Valladolid Documentary Repository (University of Valladolid) · doi:10.35376/10324/2970
Carneiro, L. (2011) · Electronic Theses of LMU Munich (Ludwig-Maximilians-Universität München) · doi:10.5282/edoc.13576
Incretin-Based Antidiabetic Agents: A New Option for Type-2 Diabetes Mellitus
Ahammad, F., Howlader, M. M., Barnab, R., Ali, M., Naher, S., & Islam, M. (2011) · Faridpur Medical College Journal · doi:10.3329/fmcj.v6i1.7412
Bowden, J. N. (2011) · Montana State University ScholarWorks (Montana State University)
Dedov, I. I., & Shestakova, M. V. (2008) · Diabetes Mellitus · doi:10.14341/2072-0351-5594
The Effects of Duodenal-jejunal Bypass on Glucose Homeostasis
Kindel, T. L. (2010) · OhioLink ETD Center (Ohio Library and Information Network)
Incretin hormones as a target for therapy
Holst, J. J. (2016) · Springer eBooks · doi:10.1007/978-3-319-08982-9_2
Self-citationTherapeutic potential of GLP-1 for treatment of diabetes
Meenakshi, & Kumar, A. N. (2015) · International journal of applied research
Herring, K. (2014)
Sayıner, Z. A., Dündar, A., & Akarsu, E. (2018) · Endocrinology research and practice. · doi:10.25179/tjem.2018-60277
Role of nanomedicines in type 2 diabetes
Kumar, A., Lama, A., Sar, S., Banerjee, T., Saha, S., Baidya, A., Chaki, R., Halder, A. K., & Ghosh, N. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-28942-2.00013-2
Decreased risk of post-thyroidectomy hypocalcemia with history of GLP-1RA use
Ayo‐Ajibola, O., Jung, T., Razura, D. E., Gallagher, T. J., Lin, M. E., Angell, T. E., & Kwon, D. I. (2025) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaf204
(2026) · Elsevier eBooks · doi:10.1016/b978-0-443-33287-6.00006-5
Туркина, С. В. (2026) · Consilium Medicum · doi:10.26442/20751753.2026.5.203661
Vikash, F., Ehsan, M., Valencia, S. O., Nadeem, A., Moazzam, E., Butsch, W. S., & Garg, S. (2026) · Nutrition in Clinical Practice · doi:10.1002/ncp.70180
BindingDB Entry 50010930: Anti-diabetic drugs recent approaches and advancements.
BindingDB (2021) · UC San Diego · doi:10.7270/q2t43xn8
BindingDB (2009) · UC San Diego · doi:10.7270/q21r6q2c
Metadata
- Authors
- Toft-Nielsen, M.-B., Madsbad, S., & Holst, J. J.
- Affiliations
- University of Copenhagen (DK)
- Corresponding author
- Holst, J. J.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2001-08
- Volume
- 86
- Issue
- 8
- Pages
- 3853-3860
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2056934377
- Cited by
- 164
- References
- 24
- Citations by year
- 2026: 4 · 2025: 2 · 2024: 5 · 2023: 1 · 2022: 2 · 2021: 2 · 2020: 7 · 2019: 9 · 2018: 7 · 2017: 5 · 2016: 8 · 2015: 9 · 2014: 14 · 2013: 16 · 2012: 9
- FWCI
- 3.45
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- Hvidovre Hospital
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- glucagon-like peptide-1, type 2 diabetes, fasting blood glucose, glucose disappearance rate, beta-cell function, insulin sensitivity, glucagon, obesity, neuropathy
- MeSH terms
- Autoantibodies, Blood Glucose, C-Peptide, Diabetes Mellitus, Type 2, Diabetic Neuropathies, Fasting, Fatty Acids, Nonesterified, Female, Glucagon, Glutamate Decarboxylase, Glycated Hemoglobin, Humans, Infusions, Intravenous, Insulin, Islets of Langerhans, Isoenzymes, Male, Middle Aged, Peptide Fragments, Protein Precursors, Regression Analysis, Body Mass Index, Dipeptidyl Peptidase 4, Area Under Curve, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.